Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that Dr. Eric von Hofe, President of Antigen Express, Inc., the Company’s wholly owned immunotherapeutics subsidiary, presented additional pre-clinical studies conducted with their immunotherapeutic peptide vaccine currently in Phase I clinical trials in patients with breast cancer. The studies were presented at the Vaccine Technology scientific symposium held in Puerto Vallarta, Mexico, June 27 - 30, 2006.
